← All trials
NCT03944434
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2018
- Primary completion
- Jun 27, 2022
- Completion date
- Nov 27, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 194
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Fondazione Sandro PitiglianiLead sponsor
- Azienda USL 4 PratoOverall official - principal investigator
- NovartisCollaborator
- Azienda USL 4 PratoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.